Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Iot symbols : Vir save search
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-02-24 (Crawled : 01:00) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -6.87%
H: 0.0%
C: 0.0%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -1.04%
H: 0.0%
C: 0.0%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -2.95%
H: 0.0%
C: 0.0%
financial results technology report results biotech iot
Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global
Published: 2022-02-08 (Crawled : 12:00) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.8%
H: 2.17%
C: -2.98%
technology biotech iot
Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria
Published: 2022-01-13 (Crawled : 15:30) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.05%
H: 1.98%
C: -6.88%
technology research antibody biotech iot hiv malaria
Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement
Published: 2021-12-31 (Crawled : 14:00) - globenewswire.com
XNCR | $18.98 -0.47% -0.47% 460K
|
Health Technology
|
| O: 0.29%
H: 1.28%
C: -1.81%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -0.86%
H: 5.64%
C: 3.97%
technology research sars-cov-2 biotech iot
Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection
Published: 2021-12-09 (Crawled : 14:30) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -1.69%
H: 6.48%
C: 2.62%
vir-2218 treatment phase 2 hepatitis technology trial biotech infection iot infections chronic hepatitis b nivolumab
Vir Biotechnology to Host a Call on Sotrovimab’s Retained Activity Against the Omicron SARS-CoV-2 Variant
Published: 2021-12-07 (Crawled : 09:00) - globenewswire.com
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -6.42%
H: 8.6%
C: 8.45%
technology biotech iot sars-cov-2
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
Published: 2021-11-17 (Crawled : 12:00) - globenewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.43%
H: 2.31%
C: 2.27%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 9.97%
H: 4.0%
C: -6.28%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
covid treatment biotech technology iot covid-19
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: 0.0%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
hepatitis potential biotech technology iot liver injection infections chronic hepatitis b
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021
Published: 2021-10-15 (Crawled : 14:00) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -0.02%
H: 3.08%
C: -2.81%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.34%
H: 0.09%
C: -0.69%
presentation hepatitis biotech technology iot liver
Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
Published: 2021-10-06 (Crawled : 22:00) - globenewswire.com
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.46%
H: 4.32%
C: 1.62%
hepatitis biotech technology iot conference
Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia– First monoclonal antibody authorized in Australia –
Published: 2021-08-23 (Crawled : 13:00) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 3.95%
H: 5.56%
C: 0.86%
antibody biotech technology iot authorized
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
Published: 2021-07-28 (Crawled : 12:00) - biospace.com/
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -1.06%
H: 1.31%
C: 1.02%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.54%
H: 4.68%
C: 0.14%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.5%
H: 1.7%
C: 1.4%
covid treatment europe biotech technology iot covid-19
Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection
Published: 2021-07-15 (Crawled : 14:00) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 0.08%
H: 2.71%
C: 2.31%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.16%
H: 1.35%
C: 1.11%
phase 2 hepatitis biotech technology iot trial injection infections chronic hepatitis b
Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021
Published: 2021-06-25 (Crawled : 13:00) - globenewswire.com
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -0.52%
H: 1.36%
C: -7.74%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.06%
H: 1.28%
C: 1.1%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.26%
H: 1.5%
C: 0.72%
hepatitis ongoing biotech technology iot liver trial injection infections chronic hepatitis b
GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab
Published: 2021-06-21 (Crawled : 12:00) - biospace.com/
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.15%
H: 0.33%
C: 0.0%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 0.5%
H: 6.27%
C: 5.89%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.32%
H: 0.17%
C: -0.13%
ev biotech technology iot
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
Published: 2021-05-26 (Crawled : 23:00) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.8%
H: 0.69%
C: 0.23%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.17%
H: 0.36%
C: -0.72%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 4.2%
H: 0.3%
C: -9.4%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.5%
H: 0.32%
C: -1.27%
covid treatment fda risk biotech technology iot merge authorized emergency use authorization
CORRECTION -- EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
Published: 2021-05-21 (Crawled : 14:00) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.21%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.24%
H: 0.96%
C: -0.06%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.75%
H: 0.13%
C: -1.44%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.43%
H: 0.2%
C: 0.02%
covid treatment positive biotech technology iot ema
EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
Published: 2021-05-21 (Crawled : 12:15) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.21%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.24%
H: 0.96%
C: -0.06%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.75%
H: 0.13%
C: -1.44%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.43%
H: 0.2%
C: 0.02%
covid treatment positive biotech technology iot ema
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
Published: 2021-05-07 (Crawled : 14:00) - biospace.com/
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.5%
H: 0.84%
C: 0.66%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.48%
H: 0.74%
C: 0.31%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 3.24%
H: 2.94%
C: 0.02%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.92%
H: 0.88%
C: 0.66%
covid treatment biotech technology iot ema
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
Published: 2021-04-21 (Crawled : 12:00) - vbivaccines.com
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -1.09%
H: 0.38%
C: 0.04%
VBIV | $0.6001 -1.46% -1.48% 180K
|
Health Technology
|
| O: 0.0%
H: 7.66%
C: 7.66%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.67%
H: 1.12%
C: 0.43%
treatment phase 2 hepatitis vbi-2601 biotech vaccine technology iot brii-835 trial
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
ZCMD | $2.44 78.1% 43.85% 330K
|
Commercial Services
XPON | $3.1 60.62% 37.74% 16M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.